medigraphic.com
Colegio de Medicina Interna de México.

2007, Número 4

<< Anterior Siguiente >>

Med Int Mex 2007; 23 (4)


Efectos de la combinación de ezetimiba más estatinas sobre los lípidos en pacientes mexicanos

Carranza MJ, Herrera CA, Lemus CH

Idioma: Español
Referencias bibliográficas: 21
Paginas: 280-285
Archivo PDF: 219.92 Kb.


RESUMEN

Antecedentes: a pesar de su eficacia, el porcentaje de pacientes tratados con estatinas que alcanzan la meta de colesterol de las lipoproteínas de baja densidad es muy bajo.
Objetivo: determinar el efecto de la combinación de ezetimiba más estatinas sobre el perfil de lípidos en pacientes mexicanos con concentraciones de C-LDL por encima de la meta.
Material y método: estudio observacional, abierto, prospectivo, ciego para los evaluadores de laboratorio, en 48 pacientes con concentraciones de C-LDL por encima de la meta correspondiente de acuerdo con los criterios del National Cholesterol Education Program, Adult Treatment Panel III. Se determinaron las concentraciones de: colesterol total, triglicéridos, colesterol de las lipoproteínas de alta densidad y se calculó el C-LDL en un laboratorio certificado por el American College of Pathologists, antes y a las ocho semanas de recibir tratamiento con estatina más 10 mg de ezetimiba.
Resultados: se alcanzó la meta de C-LDL en 83.3% de los casos. Hubo descensos significativos del colesterol total de 37%, en C-LDL de 51% y de triglicéridos de 18%. Contra lo reportado en la bibliografía, el C-HDL se redujo significativamente en 6.8%. Este descenso se observó en todos los grupos de pacientes con excepción de los que tenían hipoalfalipoproteinemia y los tratados con rosuvastatina más ezetimiba.
Conclusiones: el tratamiento con estatinas más ezetimiba provoca importantes reducciones del C-LDL en pacientes mexicanos, con efectos menores pero significativos en triglicéridos, pero la reducción importante en C-HDL, cuyas repercusiones a largo plazo se desconocen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.

  2. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001;357:577-81.

  3. Sever PS, Dahlof B, Poulter NR, Wedel H, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.

  4. Durrington PN. Dyslipidaemia. Lancet 2003;362:717-31.

  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

  6. Grundy SM, Cleeman JI, Merz CN, Brewer HB, et al. Implications of recent clinical trials for the National Cholesterol Education Program, Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.

  7. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assesment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.

  8. Foley KA, et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79-81.

  9. Alpizar M. National survey to determine the percentage of patients who reach the goals stablished by National Cholesterol Education Program (NCEP) when they are managed with statins. Diabetes 2005;54(Suppl 1):A590.

  10. Bays H, Drehobl M, Rosenblatt S, Toth P, et al. Low-density lipoprotein cholesterol reduction by SCH-58235 (ezetimibe), a novel inhibitor of intestinal cholesterol absorption in 243 hypercholesterolemic subjects: results of a dose-response study. Atherosclerosis 2000;151:135.

  11. Kosoglu T, Meyer I, Musiol B. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Atherosclerosis 2000;151:135.

  12. Kerzner B, Corbelli J, Sharp S, Lipka LJ, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418-24.

  13. Davidson MH, McGarry T, Bettis R. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34.

  14. Ballantyne CN, Houri J, Notarbartolo A, for the Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Circulation 2003;107:2409-15.

  15. Gagné C, Bays HE, Weiss SR, Mata P, for the Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91.

  16. Mackness MI, Durrington PN. High-density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243-53.

  17. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, et al. For the DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733-37.

  18. Sniderman EA. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol 2002;90:48-54.

  19. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-60.

  20. De Jongh S, Lilien MR, Roodt J, Stroes ES, et al. Early statin therapy restores endotelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002;40:2117-21.

  21. Garcia E, Carranza J, Alvarez C. Effects of bezafibrate + simvastatin and bezafibrate + ezetimibe on lipid profile and flowdependent vasodilation in hypertensive patients with hypertriglyceridemia and low HDL-cholesterol levels. Proceedings of the XVIth Scientific Meeting of the Interamerican Society of Hypertension, Cancun, Q. Roo, Mexico, april 2005:148.




2020     |     www.medigraphic.com